Edaravone Dexborneol in Large Ischemic Stroke: Real-World Experience from a Multicenter Study in China

Area of Science:

• Neurology
• Pharmacology
• Clinical Medicine

Background:

• Edaravone dexborneol is a novel neuroprotective agent with antioxidant and anti-inflammatory properties.
• It has shown promise in improving functional outcomes for acute ischemic stroke patients.
• This study focuses on its efficacy in patients with large infarct cores.

Purpose of the Study:

• To evaluate the clinical outcomes of edaravone dexborneol in patients with acute ischemic stroke and large infarct cores.
• To assess the drug's impact on functional recovery and mortality.
• To compare outcomes between patients receiving edaravone dexborneol and those who did not.

Main Methods:

• A prospective, multicenter, real-world cohort study involving 72 centers in China.
• Participants were divided into exposed (edaravone dexborneol) and unexposed groups.
• Propensity score matching (1:1) was employed to balance baseline characteristics, with the primary outcome being modified Rankin Scale score ≤2 at 90 days.

Main Results:

• Edaravone dexborneol significantly improved the 90-day modified Rankin Scale ordinal shift (OR, 1.90; P=0.04).
• Patients receiving edaravone dexborneol demonstrated higher rates of functional independence (58.8% vs. 36.8%; P=0.01).
• A trend towards lower 90-day mortality was observed in the edaravone dexborneol group (11.8% vs. 19.1%; P=0.24).

Conclusions:

• Edaravone dexborneol improves the likelihood of favorable functional outcomes at 90 days in acute ischemic stroke patients with large infarct cores.
• The agent's neuroprotective effects contribute to enhanced recovery and potentially reduced mortality.
• Real-world data supports the use of edaravone dexborneol in this patient population.